IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis : Episode 12

Opinion

Video

February 18, 2025

Safety Data With Biologics in Atopic Dermatitis

Panelists discuss the safety of biologics in atopic dermatitis (AD), reviewing current understanding of their safety profiles, including long-term data, adverse events, and the overall risk-benefit analysis for patients using these agents.

EP: 1.Heterogenous Presentation Of Atopic Dermatitis

EP: 2.Use of Biopsy and Diagnosing New-Onset AD

EP: 3.Treatment Options in Atopic Dermatitis

EP: 4.Improvement in Standard of Care in Atopic Dermatitis

EP: 5.Improvement in Patients’ Qualify of Life with Atopic Dermatitis Treatments

EP: 6.Guidance for Moving to Advanced Systemic Therapy and Biologic Agents

EP: 7.IL-13–Targeting Agents in Atopic dermatitis

EP: 8.Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

EP: 9.Less Frequent Administration of Lebrikizumab for Atopic Dermatitis

EP: 10.Switching or Staying Within the Treatment Class

EP: 11.Use of Combination Therapy in Atopic Dermatitis

EP: 12.Safety Data With Biologics in Atopic Dermatitis

Video content above is prompted by the following:

Please discuss the safety of biologics in AD. Where are we today in understanding the safety of these agents?

Related Videos

Aflibercept 8 mg Shows Durability at 3 Years in Wet AMD with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center

Investigating Brensocatib, Potential First Treatment for Bronchiectasis, with James Chalmers, MBChB, PhD

Aflibercept 8 mg Noninferior for RVO in QUASAR with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center

AI in Dermatology: Emerging Insights and Diverging Perspectives

Medical Sisterhood: James Del Rosso, DO

5 experts in this video

3 experts are featured in this series.

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.